Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma

by Egbert Oosterwijk, Peter F. A. Mulders, Jeannette C. Oosterwijk-Wakka, Otto C. Boerman
Published 2013-05-01

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

by Wieke C. H. Visser, Hans de Jong, Willem J. G. Melchers, Peter F. A. Mulders, Jack A. Schalken
Published 2020-12-01

Optimizing Lutetium 177–Anti–Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model

by Constantijn H.J. Muselaers, Egbert Oosterwijk, Desirée L. Bos, Wim J.G. Oyen, Peter F.A. Mulders, Otto C. Boerman
Published 2014-06-01

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

by Peter F. A. Mulders, Jack A. Schalken, Jelle O. Barentsz, J. P. Michiel Sedelaar, Jurgen J. Futterer, Inge M. van Oort, Elisabeth A. Wierenga, Gisele H. J. M. Leyten
Published 2013-05-01

Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI

by Maudy C. W. Gayet, Anouk A. M. A. van der Aa, Harrie P. Beerlage, Bart Ph Schrier, Maaike Gielens, Roel Heesakkers, Gerrit J. Jager, Peter F. A. Mulders, Hessel Wijkstra
Published 2020-01-01

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

by Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, William P.J. Leenders, Jeroen A.W.M. van der Laak, Otto C. Boerman, Peter F.A. Mulders, Egbert Oosterwijk
Published 2015-02-01